Myeloproliferative neoplasms and personalized medicine: the perfect match?
作者信息
Kiladjian Jean-Jacques, Harrison Claire
机构信息
Hopital Saint-Louis, APHP, Centre d'Investigations Cliniques, Paris France INSERM UMR-S 1131, Institut Universitaire d'Hématologie, Université Paris Diderot, France
Guy's and St Thomas' NHS Foundation Trust, London, UK.
出版信息
Haematologica. 2015 Dec;100(12):1493-4. doi: 10.3324/haematol.2015.137182.
Abstract
摘要
相似文献
1
Myeloproliferative neoplasms and personalized medicine: the perfect match?骨髓增殖性肿瘤与个性化医疗：完美匹配？
Haematologica. 2015 Dec;100(12):1493-4. doi: 10.3324/haematol.2015.137182.
2
Prevention and management of thrombosis in myeloproliferative neoplasms.骨髓增殖性肿瘤中血栓形成的预防与管理
Clin Adv Hematol Oncol. 2017 Mar;15(3):178-181.
3
Italian survey on clinical practice in myeloproliferative neoplasms. A GIMEMA Myeloproliferative Neoplasms Working Party initiative.意大利骨髓增殖性肿瘤临床实践调查。一项由GIMEMA骨髓增殖性肿瘤工作组发起的倡议。
Am J Hematol. 2019 Sep;94(9):E239-E242. doi: 10.1002/ajh.25555. Epub 2019 Jun 22.
4
Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.伊马替尼治疗成功作为非典型骨髓增殖性肿瘤移植的桥梁。
Curr Res Transl Med. 2019 Nov;67(4):149-151. doi: 10.1016/j.retram.2019.04.003. Epub 2019 May 30.
5
Personalized medicine in cancer: where are we today?癌症个性化医疗：我们如今处于什么阶段？
Future Oncol. 2015;11(20):2795-8. doi: 10.2217/fon.15.204. Epub 2015 Sep 7.
6
Myeloid disease.髓系疾病
Curr Opin Hematol. 2009 Mar;16(2):63. doi: 10.1097/MOH.0b013e3283279a76.
7
Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms.利用神经-造血干细胞龛轴治疗骨髓增殖性肿瘤。
Haematologica. 2019 Apr;104(4):639-641. doi: 10.3324/haematol.2018.211896.
8
Preface.前言。
Best Pract Res Clin Haematol. 2019 Mar;32(1):1-2. doi: 10.1016/j.beha.2019.02.010. Epub 2019 Feb 23.
9
The computable cell: A step toward personalized medicine.可计算细胞：迈向个性化医疗的一步。
Sci Signal. 2015 Dec 22;8(408):eg6. doi: 10.1126/scisignal.aae0544.
10
Ready or not: personalized medicine is coming. IEEE Pulse talks with Michael Snyder about its potential.准备好了吗：个性化医疗即将到来。《IEEE 脉动》杂志与迈克尔·斯奈德探讨了其潜力。
IEEE Pulse. 2014 May-Jun;5(3):45-7. doi: 10.1109/MPUL.2014.2309580.
引用本文的文献
1
Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.阐明骨髓增殖性肿瘤分子发病机制的进展及其在治疗决策中的应用。
Int J Hematol. 2020 Feb;111(2):182-191. doi: 10.1007/s12185-019-02778-9. Epub 2019 Nov 18.
2
Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.下一代测序改善了髓系肿瘤的诊断、预后和临床管理。
Cancers (Basel). 2019 Sep 13;11(9):1364. doi: 10.3390/cancers11091364.
本文引用的文献
1
A review of the European LeukemiaNet recommendations for the management of CML.欧洲白血病网关于慢性粒细胞白血病管理建议的综述。
Ann Hematol. 2015 Apr;94 Suppl 2:S141-7. doi: 10.1007/s00277-015-2322-2. Epub 2015 Mar 27.
2
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.JAK2/JAK2(V617F)抑制剂帕西替尼（SB1518）用于骨髓纤维化患者的2期研究结果。
Blood. 2015 Apr 23;125(17):2649-55. doi: 10.1182/blood-2013-02-484832. Epub 2015 Mar 11.
3
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.芦可替尼与标准疗法治疗真性红细胞增多症的对比
N Engl J Med. 2015 Jan 29;372(5):426-35. doi: 10.1056/NEJMoa1409002.
4
Therapy for myeloproliferative neoplasms: when, which agent, and how?骨髓增殖性肿瘤的治疗：何时、用哪种药物以及如何治疗？
Blood. 2014 Dec 4;124(24):3529-37. doi: 10.1182/blood-2014-05-577635.
5
Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.莫洛替尼治疗的骨髓纤维化患者反应和生存的遗传决定因素。
Leukemia. 2015 Mar;29(3):741-4. doi: 10.1038/leu.2014.306. Epub 2014 Nov 11.
6
Revised assessment of response and long-term discontinuation rates among 111 patients with myelofibrosis treated with momelotinib or ruxolitinib.对111例接受莫洛替尼或芦可替尼治疗的骨髓纤维化患者的缓解情况和长期停药率的修订评估。
Leukemia. 2015 Feb;29(2):498-500. doi: 10.1038/leu.2014.286. Epub 2014 Sep 25.
7
Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia.英国血液学标准委员会原发性血小板增多症诊断标准的修订
Br J Haematol. 2014 Nov;167(3):421-3. doi: 10.1111/bjh.12986. Epub 2014 Jun 17.
8
World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.世界卫生组织定义的嗜酸性粒细胞疾病：2014 年诊断、风险分层和管理更新。
Am J Hematol. 2014 Mar;89(3):325-37. doi: 10.1002/ajh.23664.
9
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.原发性骨髓纤维化中预后不良突变的数量和预后：一项对 797 例患者的国际研究。
Leukemia. 2014 Sep;28(9):1804-10. doi: 10.1038/leu.2014.76. Epub 2014 Feb 19.
10
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.骨髓增殖性肿瘤体细胞突变的克隆进化及其临床相关性。
Blood. 2014 Apr 3;123(14):2220-8. doi: 10.1182/blood-2013-11-537167. Epub 2014 Jan 29.
Zotero 插件